Updating Clinical Endpoint Definitions

PVRI Member Authors: Paul Hassoun, Sylvia Nikkho, Berman Rosenzweig, John Teeter, Ardeschir Ghofrani, Evangelos D. Michelakis, Ronald J. Oudiz


The 6-Minute Walk Distance (6-MWD) has been the most utilized endpoint for judging the efficacy of pulmonary arterial hypertension (PAH) therapy in clinical trials conducted over the past two decades. Despite its simplicity, widespread use in recent trials and overall prognostic value, the 6-MWD has often been criticized over the past several years and pleas from several PAH experts have emerged from the literature to find alternative endpoints that would be more reliable in reflecting the pulmonary vascular resistance as well as cardiac status in PAH and their response to therapy. A meeting of PAH experts and representatives from regulatory agencies and pharmaceutical companies was convened in early 2012 to discuss the validity of current as well as emerging valuable endpoints. The current work represents the proceedings of the conference.

Letter to the Editor

Author feedback

Read the full article online


Paul M. Hassoun, Sylvia Nikkho, Erika B. Rosenzweig, Gail Moreschi, John Lawrence, John Teeter, Christian Meier, Ardeshir H. Ghofrani, Omar Minai, Paula Rinaldi, Evangelos Michelakis, Ronald J Oudiz

Published in:

Pulmonary Circulation Vol 3: No 1 cover image

March 2013

Pulmonary Circulation Vol 3: No 1

View this journal

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI